New drug aims to outdo chemo for lung cancer patients Who've run out of options

NCT ID NCT06382116

Ongoing Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This Phase 3 trial tests a new drug called BL-B01D1 against standard chemotherapy in 432 people with advanced non-small cell lung cancer whose previous targeted therapy (EGFR-TKI) has stopped working. The study compares how long the cancer stays under control and overall survival. BL-B01D1 is given by IV every 3 weeks, and the goal is to see if it works better than chemo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BL-B01D1 (also called iza-bren or izalontamab brengitecan)
What this could lead to: If successful, this could offer a new treatment option for people with advanced lung cancer whose current targeted therapy has stopped working.
What could go wrong: This is an early-stage Phase 3 trial, so results are not yet known. The drug may not work better than chemotherapy and could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER WITH EGFR-SENSITIVE MUTATIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung adenocarcinoma non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.